{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:16Z","timestamp":1793689456939,"version":"4.5.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Eat Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>GLP-1 receptor and GIP agonists are widely used for weight loss in obesity, with strong evidence supporting their efficacy, and their potential positive impact on binge eating disorders. However, little is known about their use in individuals with eating disorders. Despite growing concerns, research exploring this intersection is limited, and clinical guidance is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This scoping review explores existing literature on weight loss injections in the context of eating disorder development and treatment to identify gaps and inform future practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The scoping review searched six electronic databases (Embase, MEDLINE, PsycINFO, AMED, HMIC, and Emcare) in April 2025. Studies were eligible if they focused on the use of weight loss injections (GLP-1 receptor agonists), in individuals with current or past eating disorders, including all diagnoses. Both clinical and non-clinical settings were included, with no age or geographical restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 80 records were identified through database searches. After title and abstract screening, 11 full-text articles were assessed for eligibility. Two papers were excluded due to the absence of empirical data, resulting in 9 studies being included in the final review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, there is very limited evidence exploring the psychological impact of GLP-1 receptor agonists on individuals with eating disorders. While some findings suggest potential benefits for managing binge eating symptoms in populations with comorbid type 2 diabetes, there is a significant gap in our understanding of how these medications may influence disordered eating behaviours and body image concerns, particularly when used outside of weight-based indicators. Further research is essential to inform clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40337-026-01634-6","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T09:44:31Z","timestamp":1782035071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms"],"prefix":"10.1186","volume":"14","author":[{"given":"Poppy","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cat","family":"Papastavrou Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"2","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/osp4.619","volume":"9","author":"KC Allison","year":"2023","unstructured":"Allison KC, Chao AM, Bruzas MB, McCuen-Wurst C, Jones E, McAllister C, et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obes Sci Pract. 2023;9(2):127\u201336. https:\/\/doi.org\/10.1002\/osp4.619.","journal-title":"Obes Sci Pract"},{"issue":"7","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1521\/jscp.2010.29.7.821","volume":"29","author":"AM Bardone-Cone","year":"2010","unstructured":"Bardone-Cone AM, Schaefer LM, Maldonado CR, Fitzsimmons EE, Harney MB, Lawson MA, et al. Aspects of self-concept and eating disorder recovery: what does the sense of self look like when an individual recovers from an eating disorder? J Soc Clin Psychol. 2010;29(7):821\u201346. https:\/\/doi.org\/10.1521\/jscp.2010.29.7.821.","journal-title":"J Soc Clin Psychol"},{"issue":"1","key":"1634_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57232","volume":"8","author":"P Berning","year":"2025","unstructured":"Berning P, Adhikari R, Schroer AE, Jelwan YA, Razavi AC, Blaha MJ, et al. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open. 2025;8(1):e2457232. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57232.","journal-title":"JAMA Netw Open"},{"key":"1634_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1330936","author":"W Chen","year":"2024","unstructured":"Chen W, Cai P, Zou W, Fu Z. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front Endocrinol. 2024. https:\/\/doi.org\/10.3389\/fendo.2024.1330936.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","volume":"14","author":"A Da Porto","year":"2020","unstructured":"Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):289\u201392. https:\/\/doi.org\/10.1016\/j.dsx.2020.03.009.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"9","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/imj.16499","volume":"54","author":"JY Gong","year":"2024","unstructured":"Gong JY, Wentworth JM. Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes. Intern Med J. 2024;54(9):1586\u20137. https:\/\/doi.org\/10.1111\/imj.16499.","journal-title":"Intern Med J"},{"issue":"2","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"AI Guerdjikova","year":"2024","unstructured":"Guerdjikova AI, Ward A, Ontiveros M, McElroy SL. Semaglutide misuse in atypical anorexia nervosa\u2014a case report. J Clin Psychopharmacol. 2024;44(2):179\u201380. https:\/\/doi.org\/10.1097\/JCP.0000000000001820.","journal-title":"J Clin Psychopharmacol"},{"key":"1634_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","volume":"7","author":"J Richards","year":"2023","unstructured":"Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS, et al. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars. 2023;7:100080. https:\/\/doi.org\/10.1016\/j.obpill.2023.100080.","journal-title":"Obes Pillars"},{"issue":"3","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","volume":"9","author":"SA Robert","year":"2015","unstructured":"Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide \u2013 a pilot study. Obes Res Clin Pract. 2015;9(3):301\u20134. https:\/\/doi.org\/10.1016\/j.orcp.2015.03.005.","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/19322968241309896","volume":"19","author":"S Seetharaman","year":"2025","unstructured":"Seetharaman S, Cengiz E. The promise of adjunct medications in improving Type 1 Diabetes outcomes: Glucagon-Like Peptide Receptor Agonists. J Diabetes Sci Technol. 2025;19(2):311\u201320. https:\/\/doi.org\/10.1177\/19322968241309896.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"1634_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40519-023-01625-5","volume":"28","author":"S Tempia Valenta","year":"2023","unstructured":"Tempia Valenta S, Stecchi M, Perazza F, Nuccitelli C, Villanova N, Pironi L, et al. Liraglutide 3.0 mg and mental health: Can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit. Eat Weight Disord - Stud Anorexia Bulimia Obes. 2023;28(1):99. https:\/\/doi.org\/10.1007\/s40519-023-01625-5.","journal-title":"Eat Weight Disord - Stud Anorexia Bulimia Obes"},{"key":"1634_CR13","doi-asserted-by":"publisher","unstructured":"Barrett P. Weight loss injections. 202 5.\u00a0 https:\/\/doi.org\/10.17605\/OSF.IO\/NAVUJ","DOI":"10.17605\/OSF.IO\/NAVUJ"},{"key":"1634_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1634_CR15","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). American Psychiatric Association Publishing. 2022. https:\/\/doi.org\/10.1176\/appi.books.9780890425787","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"7","key":"1634_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","volume":"68","author":"J Arcelus","year":"2011","unstructured":"Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with Anorexia Nervosa and other eating disorders: A meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.74.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, Roux L, Ho CW, Falcon W, Valderas BLG, et al. Tirzepatide as compared with Semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"issue":"9","key":"1634_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093122","volume":"14","author":"M Ka\u0142as","year":"2025","unstructured":"Ka\u0142as M, St\u0119pniewska E, Gniedziejko M, Leszczy\u0144ski-Czeczatka J, Siemi\u0144ski M. Glucagon-like Peptide-1 Receptor Agonists in the context of eating disorders: A promising therapeutic option or a double-edged sword? J Clin Med. 2025;14(9):3122. https:\/\/doi.org\/10.3390\/jcm14093122.","journal-title":"J Clin Med"},{"key":"1634_CR22","unstructured":"Limited C, Robertson J. (2025, May 12). Around 1.5 million UK citizens used weight-loss jabs in March 2025. The Pharmacist. https:\/\/www.thepharmacist.co.uk\/clinical\/cardiovascular\/around-1-5-million-uk-citizens-used-weight-loss-jabs-in-march-2025\/"},{"key":"1634_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.mehy.2017.12.029","volume":"111","author":"SL McElroy","year":"2018","unstructured":"McElroy SL, Mori N, Guerdjikova AI, Keck PE. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Med Hypotheses. 2018;111:90\u20133. https:\/\/doi.org\/10.1016\/j.mehy.2017.12.029.","journal-title":"Med Hypotheses"},{"issue":"1","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40337-025-01187-0","volume":"13","author":"B Melisse","year":"2025","unstructured":"Melisse B, Dingemans A. Redefining diagnostic parameters: the role of overvaluation of shape and weight in binge-eating disorder: a systematic review. J Eat Disord. 2025;13(1):9. https:\/\/doi.org\/10.1186\/s40337-025-01187-0.","journal-title":"J Eat Disord"},{"issue":"1","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s40519-025-01720-9","volume":"30","author":"H Radkhah","year":"2025","unstructured":"Radkhah H, Rahimipour Anaraki S, Parhizkar Roudsari P, Arabzadeh Bahri R, Zooravar D, Asgarian S, et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eat Weight Disord. 2025;30(1):10. https:\/\/doi.org\/10.1007\/s40519-025-01720-9.","journal-title":"Eat Weight Disord"},{"issue":"7","key":"1634_CR26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049\u201357. https:\/\/doi.org\/10.1038\/s41591-024-02996-7.","journal-title":"Nat Med"},{"issue":"5","key":"1634_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1017\/S0033291718001472","volume":"49","author":"K Schaumberg","year":"2019","unstructured":"Schaumberg K, Jangmo A, Thornton LM, Birgeg\u00e5rd A, Almqvist C, Norring C, et al. Patterns of diagnostic transition in eating disorders: a longitudinal population study in Sweden. Psychol Med. 2019;49(5):819\u201327. https:\/\/doi.org\/10.1017\/S0033291718001472.","journal-title":"Psychol Med"},{"issue":"3","key":"1634_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40519-021-01226-0","volume":"27","author":"R Serra","year":"2022","unstructured":"Serra R, Di Nicolantonio C, Di Febo R, De Crescenzo F, Vanderlinden J, Vrieze E, et al. The transition from restrictive anorexia nervosa to binging and purging: a systematic review and meta-analysis. Eat Weight Disord. 2022;27(3):857\u201365. https:\/\/doi.org\/10.1007\/s40519-021-01226-0.","journal-title":"Eat Weight Disord"},{"key":"1634_CR29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71569","author":"LG Shareef","year":"2024","unstructured":"Shareef LG, Khalid SS, Raheem MF, Al-Hussainy AF, Al-Khayyat NS, Al Arajy AZ, et al. Population-level interest in glucagon-like Peptide-1 receptor agonists for weight loss using Google Trends statistics in a 12-month retrospective analysis: an infodemiology and infoveillance study. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.71569.","journal-title":"Cureus"},{"issue":"1","key":"1634_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/erv.2805","volume":"29","author":"M Vervaet","year":"2021","unstructured":"Vervaet M, Puttevils L, Hoekstra RHA, Fried E, Vanderhasselt M. Transdiagnostic vulnerability factors in eating disorders: a network analysis. Eur Eat Disorders Rev. 2021;29(1):86\u2013100. https:\/\/doi.org\/10.1002\/erv.2805.","journal-title":"Eur Eat Disorders Rev"},{"issue":"1","key":"1634_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13054-024-04945-9","volume":"28","author":"L Wang","year":"2024","unstructured":"Wang L, Yang H, Xia X, Wang B, Wu Q. Potential implications of long-acting GLP-1 receptor agonists for critically ill. Crit Care. 2024;28(1):159. https:\/\/doi.org\/10.1186\/s13054-024-04945-9.","journal-title":"Crit Care"},{"issue":"1","key":"1634_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000194641","volume":"2","author":"H Wolter","year":"2009","unstructured":"Wolter H, Schneider N, Pfeiffer E, Lehmkuhl U. Diagnostic crossover from obesity to atypical anorexia nervosa - a case report. Obes Facts. 2009;2(1):52\u20133. https:\/\/doi.org\/10.1159\/000194641.","journal-title":"Obes Facts"},{"issue":"2","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292\u2013300. https:\/\/doi.org\/10.2337\/dc24-1678.","journal-title":"Diabetes Care"},{"key":"1634_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang C-Z, Wan J-Y, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"key":"1634_CR35","doi-asserted-by":"publisher","DOI":"10.12775\/QS.2024.20.53875","volume":"20","author":"MM Zaj\u0105c","year":"2024","unstructured":"Zaj\u0105c MM, Zaucha R, Silldorff J, Anczyk S, Dudek M, Fura T, et al. Injections for weight loss: what\u2019s new in GLP-1 RAs for obesity treatment \u2013 review. Qual Sport. 2024;20:53875. https:\/\/doi.org\/10.12775\/QS.2024.20.53875.","journal-title":"Qual Sport"},{"issue":"3","key":"1634_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030136","volume":"13","author":"G Amorim Moreira Alves","year":"2025","unstructured":"Amorim Moreira Alves G, Teranishi M, Teixeira De Castro Gon\u00e7alves Ortega AC, James F, Perera Molligoda Arachchige AS. Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights. Medical Sciences. 2025;13(3):136. https:\/\/doi.org\/10.3390\/medsci13030136.","journal-title":"Medical Sciences"},{"issue":"2","key":"1634_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jhealeco.2007.05.005","volume":"27","author":"RV Burkhauser","year":"2008","unstructured":"Burkhauser RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ. 2008;27(2):519\u201329. https:\/\/doi.org\/10.1016\/j.jhealeco.2007.05.005.","journal-title":"J Health Econ"},{"issue":"1","key":"1634_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jclinepi.2006.03.014","volume":"60","author":"J Daly","year":"2007","unstructured":"Daly J, Willis K, Small R, Green J, Welch N, Kealy M, et al. A hierarchy of evidence for assessing qualitative health research. J Clin Epidemiol. 2007;60(1):43\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.014.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1634_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-013-0396-x","volume":"15","author":"GKW Frank","year":"2013","unstructured":"Frank GKW. Altered brain reward circuits in eating disorders: chicken or egg? Curr Psychiatry Rep. 2013;15(10):396. https:\/\/doi.org\/10.1007\/s11920-013-0396-x.","journal-title":"Curr Psychiatry Rep"},{"key":"1634_CR43","unstructured":"Frisbie M, The danger online pharmacies pose on clients with eating disorders in the prescription of GLP-1 agonists for weight loss. (2024). Sel Honors Theses. https:\/\/firescholars.seu.edu\/honors\/194"},{"issue":"4","key":"1634_CR44","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1332\/174426421X16856230946027","volume":"19","author":"BW Gac","year":"2023","unstructured":"Gac BW, Yakubi H, Apollonio DE. Issues arising from the study design, conduct, and promotion of clinical trials funded by opioid manufacturers: a review of internal pharmaceutical industry documents. Evid Policy. 2023;19(4):536\u201353. https:\/\/doi.org\/10.1332\/174426421X16856230946027.","journal-title":"Evid Policy"},{"issue":"3","key":"1634_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ajcn\/72.3.694","volume":"72","author":"D Gallagher","year":"2000","unstructured":"Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000;72(3):694\u2013701. https:\/\/doi.org\/10.1093\/ajcn\/72.3.694.","journal-title":"Am J Clin Nutr"},{"key":"1634_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2015.01608","author":"LR Godier","year":"2015","unstructured":"Godier LR, Park RJ. Does compulsive behavior in Anorexia Nervosa resemble an addiction? A qualitative investigation. Front Psychol. 2015. https:\/\/doi.org\/10.3389\/fpsyg.2015.01608.","journal-title":"Front Psychol"},{"issue":"1","key":"1634_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/S0954422409990035","volume":"22","author":"M Harrington","year":"2009","unstructured":"Harrington M, Gibson S, Cottrell RC. A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev. 2009;22(1):93\u2013108. https:\/\/doi.org\/10.1017\/S0954422409990035.","journal-title":"Nutr Res Rev"},{"issue":"2","key":"1634_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1192\/bjp.2019.174","volume":"216","author":"M Herle","year":"2020","unstructured":"Herle M, Stavola BD, H\u00fcbel C, Abdulkadir M, Ferreira DS, Loos RJF, et al. A longitudinal study of eating behaviours in childhood and later eating disorder behaviours and diagnoses. Br J Psychiatry. 2020;216(2):113\u20139. https:\/\/doi.org\/10.1192\/bjp.2019.174.","journal-title":"Br J Psychiatry"},{"issue":"12","key":"1634_CR49","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.neuron.2025.04.029","volume":"113","author":"HE Hulshoff Pol","year":"2025","unstructured":"Hulshoff Pol HE, Brouwer RM. Unique opportunities and challenges of longitudinal approaches in studying brain health and mental health. Neuron. 2025;113(12):1858\u201361. https:\/\/doi.org\/10.1016\/j.neuron.2025.04.029.","journal-title":"Neuron"},{"issue":"10","key":"1634_CR50","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/j.1875-9114.2012.01123","volume":"32","author":"EJ Ip","year":"2012","unstructured":"Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910\u20139. https:\/\/doi.org\/10.1002\/j.1875-9114.2012.01123.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1634_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1054-139X(01)00414-1","volume":"30","author":"L Irving","year":"2002","unstructured":"Irving L, Wall M, Neumarksztainer D, Story M. Steroid use among adolescents: findings from Project EAT. J Adolesc Health. 2002;30(4):243\u201352. https:\/\/doi.org\/10.1016\/S1054-139X(01)00414-1.","journal-title":"J Adolesc Health"},{"issue":"1","key":"1634_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s40519-023-01635-3","volume":"29","author":"HH Jaiprakash","year":"2024","unstructured":"Jaiprakash HH, MacKinnon A, Arnaud S, Neal JP. Valuing patient perspectives in the context of eating disorders. Eat Weight Disorders - Stud Anorexia Bulimia Obes. 2024;29(1):12. https:\/\/doi.org\/10.1007\/s40519-023-01635-3.","journal-title":"Eat Weight Disorders - Stud Anorexia Bulimia Obes"},{"issue":"12","key":"1634_CR54","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","volume":"104","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic\u2013androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966\u201378. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02734.x.","journal-title":"Addiction"},{"issue":"2","key":"1634_CR55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0899-3289(05)80039-2","volume":"3","author":"DD Krahn","year":"1991","unstructured":"Krahn DD. The relationship of eating disorders and substance abuse. J Subst Abuse. 1991;3(2):239\u201353. https:\/\/doi.org\/10.1016\/S0899-3289(05)80039-2.","journal-title":"J Subst Abuse"},{"key":"1634_CR56","unstructured":"Krentz A, Chew J, Arthur N. Recovery from Binge Eating Disorder. Can J Counselling Psychother, 39(2). 2005.\u00a0https:\/\/cjc-rcc.ucalgary.ca\/article\/view\/58756"},{"issue":"3","key":"1634_CR57","doi-asserted-by":"publisher","first-page":"e0121993","DOI":"10.1371\/journal.pone.0121993","volume":"10","author":"SB Kritchevsky","year":"2015","unstructured":"Kritchevsky SB, Beavers KM, Miller ME, Shea MK, Houston DK, Kitzman DW, Nicklas BJ. Intentional Weight Loss and All-Cause Mortality: A Meta-Analysis of Randomized Clinical Trials. PLoS ONE. 2015;10(3):e0121993. https:\/\/doi.org\/10.1371\/journal.pone.0121993.","journal-title":"PLoS ONE"},{"issue":"1","key":"1634_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40337-020-0279-6","volume":"8","author":"RS Lewke-Bandara","year":"2020","unstructured":"Lewke-Bandara RS, Thapliyal P, Conti J, Hay P. It also taught me a lot about myself: A qualitative exploration of how men understand eating disorder recovery. J Eat Disorders. 2020;8(1):3. https:\/\/doi.org\/10.1186\/s40337-020-0279-6.","journal-title":"J Eat Disorders"},{"issue":"4","key":"1634_CR59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/JRS-2012-0574","volume":"24","author":"J Lexchin","year":"2012","unstructured":"Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med. 2012;24(4):233\u201342. https:\/\/doi.org\/10.3233\/JRS-2012-0574.","journal-title":"Int J Risk Saf Med"},{"issue":"1","key":"1634_CR60","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1345\/aph.1E224","volume":"39","author":"JR Lexchin","year":"2005","unstructured":"Lexchin JR. Implications of pharmaceutical industry funding on clinical research. Ann Pharmacother. 2005;39(1):194\u20137. https:\/\/doi.org\/10.1345\/aph.1E224.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1634_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1751-0759-2-5","volume":"2","author":"H Nishimura","year":"2008","unstructured":"Nishimura H, Komaki G, Ando T, Nakahara T, Oka T, Kawai K, Nagata T, Nishizono A, Okamoto Y, Okabe K, Koide M, Yamaguchi C, Saito S, Ohkuma K, Nagata K, Naruo T, Takii M, Kiriike N, Ishikawa T. Psychological and weight-related characteristics of patients with anorexia nervosa-restricting type who later develop bulimia nervosa. Biopsychosoc Med. 2008;2(1):5. https:\/\/doi.org\/10.1186\/1751-0759-2-5. Japanese Genetic Research Group for Eating Disorders.","journal-title":"Biopsychosoc Med"},{"issue":"1","key":"1634_CR63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","volume":"26","author":"EM Oehrlein","year":"2023","unstructured":"Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, et al. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26(1):28\u201338. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1738.","journal-title":"Value Health"},{"key":"1634_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.924815","volume":"13","author":"MA Peterson Pel\u00e1ez-Fern\u00e1ndez","year":"2022","unstructured":"Peterson Pel\u00e1ez-Fern\u00e1ndez MA, Sep\u00falveda AR, Compte EJ. Editorial: eating disorders and weight disorders: assessment, early diagnosis, prognosis, treatment outcome and the role of potential psychological and social factors. Front Psychol. 2022;13:924815. https:\/\/doi.org\/10.3389\/fpsyg.2022.924815.","journal-title":"Front Psychol"},{"issue":"3","key":"1634_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1573399813666170414101450","volume":"14","author":"SC Peterson","year":"2018","unstructured":"Peterson SC, Barry AR. Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis. Curr Diabetes Rev. 2018;14(3):273\u20139. https:\/\/doi.org\/10.2174\/1573399813666170414101450.","journal-title":"Curr Diabetes Rev"},{"issue":"1","key":"1634_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3961\/jpmph.22.451","volume":"56","author":"J Pyo","year":"2023","unstructured":"Pyo J, Lee W, Choi EY, Jang SG, Ock M. Qualitative research in healthcare: necessity and characteristics. J Prev Med Public Health. 2023;56(1):12\u201320. https:\/\/doi.org\/10.3961\/jpmph.22.451.","journal-title":"J Prev Med Public Health"},{"issue":"8","key":"1634_CR67","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/eat.23294","volume":"53","author":"TK Richmond","year":"2020","unstructured":"Richmond TK, Woolverton GA, Mammel K, Ornstein RM, Spalding A, Woods ER, et al. How do you define recovery? A qualitative study of patients with eating disorders, their parents, and clinicians. Int J Eat Disord. 2020;53(8):1209\u201318. https:\/\/doi.org\/10.1002\/eat.23294.","journal-title":"Int J Eat Disord"},{"issue":"9","key":"1634_CR68","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.socscimed.2008.01.010","volume":"66","author":"S Sismondo","year":"2008","unstructured":"Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66(9):1909\u201314. https:\/\/doi.org\/10.1016\/j.socscimed.2008.01.010.","journal-title":"Soc Sci Med"},{"key":"1634_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104854","volume":"142","author":"LA Turnock","year":"2025","unstructured":"Turnock LA, Hearne E, Germain J, Hirst M, Townshend HD, Lazuras L. Off-label GLP-1 weight-loss medicine use among online bodybuilders: folk pharmacology, risk and harm reduction. Int J Drug Policy. 2025;142:104854. https:\/\/doi.org\/10.1016\/j.drugpo.2025.104854.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1634_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.fhj.2025.100263","volume":"12","author":"C van Tulleken","year":"2025","unstructured":"van Tulleken C. Ultra-processed foods and public health: evidence of harm and of conflicts of interest in the food industry to evade regulation. Future Healthc J. 2025;12(2):100263. https:\/\/doi.org\/10.1016\/j.fhj.2025.100263.","journal-title":"Future Healthc J"},{"key":"1634_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113143","volume":"290","author":"M Wade","year":"2020","unstructured":"Wade M, Prime H, Browne DT. Why we need longitudinal mental health research with children and youth during (and after) the COVID-19 pandemic. Psychiatry Res. 2020;290:113143. https:\/\/doi.org\/10.1016\/j.psychres.2020.113143.","journal-title":"Psychiatry Res"},{"key":"1634_CR73","doi-asserted-by":"publisher","unstructured":"Anderson JD, Newby R, Kehm R, Barland P, Hearst MO (2015) Taking Steps Together: A Family- and Community-Based Obesity Intervention for Urban, Multiethnic Children. Health Edu Behav 42(2):194\u2013201. https:\/\/doi.org\/10.1177\/1090198114547813","DOI":"10.1177\/1090198114547813"},{"key":"1634_CR74","doi-asserted-by":"publisher","unstructured":"Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J, Morcos Z, Al Saidi I, Bou Sanayeh E, Saliba S, Almardini M, Zaidan J (2024) GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. J Clin Trans Endocrinol 35:100333. https:\/\/doi.org\/10.1016\/j.jcte.2024.100333","DOI":"10.1016\/j.jcte.2024.100333"},{"key":"1634_CR75","doi-asserted-by":"publisher","unstructured":"Da Porto A, Varisco E, Antonello M, Casarsa V, Sechi LA (2024) Semaglutide Treatment in Adult-Onset Autoimmune Diabetes: A Case Study With Long-Term Follow-Up and Periodic Evaluation of Beta-Cell Function. Cureus. https:\/\/doi.org\/10.7759\/cureus.55771","DOI":"10.7759\/cureus.55771"},{"key":"1634_CR76","doi-asserted-by":"publisher","unstructured":"Goldfield GS (2009) Predictors of Response to an Intervention Modifying Physical Activity and Sedentary Behavior in Overweight\/Obese Children: Attitudes vs. Behavior. J Phys Activity Health 6(4):463\u2013466. https:\/\/doi.org\/10.1123\/jpah.6.4.463","DOI":"10.1123\/jpah.6.4.463"},{"key":"1634_CR77","doi-asserted-by":"publisher","unstructured":"Piacentino D, Kotzalidis GD, Longo L, Pavan A, Stivali L, Stivali G, Ferracuti S, Brugnoli R, Frati P, Fineschi V, Girardi P, Sani G (2017. Body Image and Eating Disorders are Common among Professional and Amateur Athletes Using Performance and Image Enhancing Drugs: A Cross-Sectional Study. J Psychoact Drugs 49(5):373\u2013384. https:\/\/doi.org\/10.1080\/02791072.2017.1359708","DOI":"10.1080\/02791072.2017.1359708"},{"key":"1634_CR78","doi-asserted-by":"publisher","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. New Engl J Med 384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","DOI":"10.1056\/NEJMoa2032183"}],"container-title":["Journal of Eating Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40337-026-01634-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-026-01634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-026-01634-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:37:52Z","timestamp":1787150272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40337-026-01634-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1186\/s40337-026-01634-6","relation":{},"ISSN":["2050-2974"],"issn-type":[{"value":"2050-2974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"194"}}